Atopic Dermatitis

There is a high risk for contact dermatitis in retail products for skincare, due to the prevalence of allergens.

Matthew Brunner, PA, shares his advice for engaging pediatric patients with atopic dermatitis in their treatment and disease care, while Lakshi Aldredge, MSN, ANP-BC, DCNP, discusses her treatment protocols.

A panel of experts in dermatology management provide insight into the role of multidisciplinary care for pediatric patients with atopic dermatitis.

The novel OX40 inhibitor molecule showed significant benefit for patients in new EADV 2022 data. A lead author discusses its potential.

The Icahn investigator discusses her team's new EADV 2022 data on the JAK inhibitor.

A pair of phase 3 clinical trials presented at EADV 2022 indicate dupilumab significantly improves PN symptoms over 24 weeks.

Experts in dermatology review the indications and evolution of the use of dupilumab in patients with atopic dermatitis, highlighting its recent approval for patients 6 months and older.

Brittany G. Craiglow, MD, discusses the efficacy and safety of upadacitinib and describes her clinical experiences with this treatment.

Melodie Young, NP; Alexa Hetzel, MA, PA-C; and Matthew Brunner, PA, discuss their approach to a clinical examination of patients with pediatric atopic dermatitis.

Experts in dermatology describe their clinical experiences of atopic dermatitis presentation in their patients, focusing on the heterogeneity across age groups and races.

Brittany G. Craiglow, MD, and Peter A. Lio, MD, provide insight into the efficacy and safety of currently available JAK inhibitors for the treatment of pediatric atopic dermatitis.

Raj Chovatiya, MD, PhD, highlights recent advances in pediatric atopic dermatitis treatments and discusses considerations regarding their use and indications.

Lakshi Aldredge, MSN, ANP-BC, DCNP, provides an overview of the prevalence of atopic dermatitis across age groups and discusses the impact of itch on these patients.

Melodie Young, NP; Alexa Hetzel, MA, PA-C; and Matthew Brunner, PA, provide insight into pediatric atopic dermatitis, highlighting disease recurrence and symptomology.

A recent study in Finland finds 2 major contributing factors to allergic disease in infants with familial risk.

Peter A. Lio, MD, describes the challenges pediatric patients face with oral therapies for atopic dermatitis, focusing on ease of administration and patient adherence.

Raj Chovatiya, MD, PhD; Brittany G. Craiglow, MD; and Peter A. Lio, MD, highlight challenges physicians face with the available atopic dermatitis treatments for pediatric patients.

A recent study indicated no evident VTE risk in patients with eczema, despite FDA black box warnings for the drug class.

Dr Peter A. Lio shares his advice for curating an atopic dermatitis treatment plan and explains the difference between rescue and maintenance treatments.

Dr Brittany G. Craiglow provides an overview of her approach to use of nonpharmacological agents in the treatment of her pediatric patients with atopic dermatitis.

Investigators found that body surface area involvement on admission, malignant neoplasm, and connective tissue disease were independent factors associated with leukopenia in SJS/TEN.

Dermatologists addressed the overprescribing of antibiotics while acknowledging the necessity of antibiotics. Excessive prescribing practices contribute to the emergence of antibiotic resistance and furthers a patient's risk for resistant infections and treatment failures.

Raj Chovatiya, MD, PhD, and Brittany G. Craiglow, MD, share their opinions on how they assess and what they define as treatment success in their pediatric patients suffering from atopic dermatitis.

Experts in dermatology review the treatment landscape for pediatric patients with atopic dermatitis.

Both treatments showed tolerable safety as in the phase 2 and 3 trials, but when evaluated in four body regions on patients, upadacitinib surpassed dupilumab in all of them.